Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine.
Vaccine
; 25(2): 373-80, 2007 Jan 04.
Article
in En
| MEDLINE
| ID: mdl-16930784
ABSTRACT
We evaluated the cost-effectiveness of rotavirus vaccination in Uzbekistan from the healthcare system and societal perspectives. Disease burden was estimated using national statistics on hospitalizations and deaths, and international estimates of under-five mortality. Without vaccination, the risk for rotavirus hospitalization by age 5 is 10 per 1000 children. Rotavirus hospitalizations cost US$ 406,000 annually, of which US$ 360,000 (89%) is for medical expenses and US$ 46,000 (11%) is for non-medical and indirect costs. Rotavirus mortality rate at 0.7 per 1000 derived from national data was three-fold lower than the same rate calculated from international estimates of under-five mortality. Rotavirus vaccination could reduce hospitalizations and deaths by 91% and avert US$ 370,000 in hospitalization costs alone. Vaccination would be cost-effective with vaccine prices in a range of US$ 2-25 per child. However, the cost-effectiveness is greatly influenced by mortality, vaccine price and vaccine efficacy.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Vaccination
/
Rotavirus Vaccines
Type of study:
Health_economic_evaluation
Limits:
Adolescent
/
Adult
/
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
/
Middle aged
/
Newborn
Language:
En
Journal:
Vaccine
Year:
2007
Document type:
Article
Affiliation country:
United States